Document is current
Any future updates will be listed below
-
Authors
Dupuis, Claire
Sabra, Ayman
Patrier, Juliette
Chaize, Gwendoline
Saighi, Amine
Féger, Céline
Vainchtock, Alexandre
Gaillat, Jacques
Timsit, Jean-François https://orcid.org/0000-0002-6063-7383
-
Funding
Funding for this research was provided by:
Pfizer France
- License Information
-
More Information
Article History
Received: 12 September 2020
Accepted: 16 December 2020
First Online: 10 January 2021
Ethics approval and consent to participate
: Not applicable, study on existing administrative database.
: Not applicable.
: CD and JP have no competing interests. AyS and AmS are employees of Pfizer France. CF is CEO of EMIBiotech, contracted by Pfizer to contribute to coordinate the study results discussion and the draft of the manuscript. GC and AV are employees of HEVA, contracted by Pfizer France to conduct the statistical analysis. JG is a member of advisory boards and gave lectures for Pfizer, Sanofi, and MSD. JFT received fees for advisory boards of Astellas, Bayer, Beckton-Dickinson, Gilead, Medimune, Merck, Nabriva, Paratek, and Pfizer. The research group of JFT received grants from 3 M, Merck, Pfizer; JFT is the principal investigator of one RCT of CAP sponsored by the French ministry of health (MULTICAP; PHRCN-16–0595; ClinicalTrials.gov Identifier: NCT03452826).
